Using a new blood test to monitor ovarian cancer after treatment
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new blood-based test (OCS) that looks for tiny particles from tumor cells to watch for cancer returning after initial treatment. It is for women with ovarian cancer whose CA125 levels were normal before starting treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman over 18 years old.
- You have been diagnosed with stage I–IV epithelial ovarian cancer.
- Your CA125 level was 35 U/ml or less before your first treatment.
- You have had surgery and chemotherapy for your ovarian cancer.
- You have not been treated for any other cancer in the past 5 years.
- You are willing to give blood samples for the OCS test during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new blood test that may help detect ovarian cancer earlier. Researchers want to see if it can tell the difference between people with ovarian cancer and those without it.
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
This study looks at how well a blood test called CA-125, along with other markers and checkups, can detect ovarian cancer early. It’s for women considered low risk who will do regular blood tests and possibly a vaginal ultrasound if results suggest it.
This study is testing a new way to predict if ovarian cancer will come back after treatment. By looking at tiny particles called exosomes in your blood, researchers hope to create a score that can guide future care.
This study looks at tumor tissue from ovarian cancer patients to find “biomarkers,” or lab signals, that may predict how the disease behaves or how it might respond to treatment. You may be asked for a biopsy of the relapsed (coming back) tumor or to use an existing archived tumor sample.
This laboratory study uses ovarian cancer fluid collected during surgery to test possible new treatments on cancer and immune cells. It may help researchers find better treatment options in ovarian cancer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.